Pediatric Inflammatory Bowel Disease
Perspective and ConsequencesEditor(s): Walker-Smith J.A. (London)
Lebenthal E. (Jerusalem)
Branski D. (Jerusalem)
Growth and Puberty in Inflammatory Bowel DiseaseSavage M.O. · Beattie R.M. · Sanderson I.R.S.
Departments of Paediatric Endocrinology and Gastroenterology, Barts and the London School of Medicine and Dentistry, London, and Department of Paediatrics, Southampton General Hospital, Southampton, UK
Professor M. O. Savage, Department of Endocrinology, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ (UK), Tel. +44 20 7882 6233, Fax +44 20 7882 6234, E-Mail email@example.com
Do you have an account?
Growth failure and delayed puberty are important features of many patients with inflammatory bowel disease, particularly those with Crohn’s disease. In Crohn’s disease growth may be abnormal before diagnosis and height is inversely proportional to the length of delay in diagnosis. Height is particularly abnormal in patients with jejunal disease. During the course of the illness growth rate is often low, although only 25% of patients develop short stature. Final adult height is decreased, but shows improvement compared with height at diagnosis. The inflammatory process appears to contribute to abnormal growth, through cytokine-induced disturbance of the IGF system. This can be corrected by regimens of enteral nutrition. Genetic factors may influence height as shown by the effect of a polymorphism of the IL-6 gene which was linked to shortness at diagnosis. Therapy for growth failure should aim to induce remission in the primary disease. In prepubertal patients with localized colonic disease intestinal resection has been followed by excellent catch-up growth. Delayed puberty is common and may be treated in boys by short-term testosterone replacement which can induce catch-up growth and improve confidence significantly.
© 2009 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.